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Abstract
Background: Clinical association studies have yielded varied results regarding the impact of glucose-6-phosphate
dehydrogenase (G6PD) deficiency upon susceptibility to malaria. Analyses have been complicated by varied methods used
to diagnose G6PD deficiency.
Methodology/Prinicipal Findings: We compared the association between uncomplicated malaria incidence and G6PD
deficiency in a cohort of 601 Ugandan children using two different diagnostic methods, enzyme activity and G6PD
genotype (G202A, the predominant East African allele). Although roughly the same percentage of males were identified as
deficient using enzyme activity (12%) and genotype (14%), nearly 30% of males who were enzymatically deficient were wild-
type at G202A. The number of deficient females was three-fold higher with assessment by genotype (21%) compared to
enzyme activity (7%). Heterozygous females accounted for the majority (46/54) of children with a mutant genotype but
normal enzyme activity. G6PD deficiency, as determined by G6PD enzyme activity, conferred a 52% (relative risk [RR] 0.48,
95% CI 0.31–0.75) reduced risk of uncomplicated malaria in females. In contrast, when G6PD deficiency was defined based
on genotype, the protective association for females was no longer seen (RR = 0.99, 95% CI 0.70–1.39). Notably, restricting
the analysis to those females who were both genotypically and enzymatically deficient, the association of deficiency and
protection from uncomplicated malaria was again demonstrated in females, but not in males (RR = 0.57, 95% CI 0.37–0.88
for females).
Conclusions/Significance: This study underscores the impact that the method of identifying G6PD deficient individuals has
upon association studies of G6PD deficiency and uncomplicated malaria. We found that G6PD-deficient females were
significantly protected against uncomplicated malaria, but this protection was only seen when G6PD deficiency is described
using enzyme activity. These observations may help to explain the discrepancy in some published association studies
involving G6PD deficiency and uncomplicated malaria.
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Introduction
Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the first
step of the pentose phosphate pathway, which converts glucose
into pentose sugars for glycolysis and other biological reactions.
The pentose phosphate pathway is the only source of reduced
nicotinamide adenine dinucleotide phosphate (NADPH) in
erythrocytes, and therefore the principal means by which
erythrocytes counteract oxidative stress [1]. Deficiency in G6PD
was first described in the 1950s as the cause of hemolysis in
response to the antimalarial drug primaquine [2]. G6PD
deficiency is the most common enzymopathy worldwide, affecting
approximately 330 million people [3]. Deficiency is caused by
mutations in the X-linked G6PD gene, in which more than 160
mutations have been identified [4,5].
Malaria has exerted a tremendous selective pressure on the
human genome, with an estimated 300–660 million cases of P.
falciparum malaria, leading to approximately 1 million deaths each
year [6,7]. Many factors contribute to an individual’s risk of
malaria, including immunity from prior infections, age, genetic
factors, use of preventive measures, and proximity to mosquito
breeding sites [8,9]. Coincident to the discovery of G6PD
deficiency as the cause of antimalarial induced hemolysis, a strong
geographical overlap was noted between the prevalence of G6PD
deficiency and malaria endemicity [10,11]. Based on this
observation, it was hypothesized that G6PD deficiency had arisen
as a protective factor against lethal malaria [10,11]. Since that
initial observation, dozens of clinical association studies have been
performed, yielding varied results. Selected studies of severe
disease showed a decrease in the risk of severe malaria in
hemizygous males [12,13] and either a reduced risk [13] or no
association with risk in heterozygous females [12]. Studies of
uncomplicated malaria have been more inconsistent, showing
G6PD deficiency to be protective in heterozygous females
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[8,13–15] or to have no effect on the incidence of uncomplicated
malaria in either hemizygous males or heterozygous females [16].
Conversely, other studies showed an increase in the incidence of
uncomplicated malaria in females heterozygous for G6PD
deficiency [17,18]. Definitive conclusions based on these results
are difficult because studies differed in design, clinical phenotype
assessed (severe or uncomplicated malaria), or methods to identify
G6PD deficiency.
Most clinical screening tests measure the enzymatic formation
of NADPH from NADP, such as the semiquantitative fluorescent
spot test or the quantitative spectrophotometric test [19–22].
Many methodological issues exist with such tests, including the
correct sample handling and storage, optimal anticoagulant for
collection, and the use of appropriate control samples [23]. In
addition, heterozygous females pose a particular challenge due to
the phenomenon of variable X chromosome inactivation or
lyonization. As a result, enzyme activity may vary depending on
the proportion of normal and deficient cells which are inactivated
in each individual [24]. G6PD deficiency may also be assessed by
analysis for mutations in the G6PD gene [25–27]. The G6PD A-
allele, which contains two mutations, G376A and G202A, is the
most common G6PD deficiency variant in Africa, with a
frequency of 0–25% [28]. The G376A mutation by itself results
in the G6PD A allele, with 80% of the enzyme activity of wild type
G6PD. When this mutation occurs in combination with G202A,
the resultant G6PD A- allele produces an enzyme with
approximately 12% the activity of wild-type G6PD [25,26].
G202A nearly always occurs in the background of the mutation at
position G376A [29–31]. Two other G6PD A- alleles, which
account for 5% of this genotype, are due to mutations at
nucleotide positions 680 or 968 in the setting of G376A [25]. In
addition, recent evidence suggests that another low frequency
mutation at position 542 may be present in West Africans [32]. As
conflicting conclusions regarding malaria risk and G6PD deficien-
cy may have been due to different detection methods, we
characterized G6PD status by both enzymatic and genotypic
assays in a cohort of Ugandan children and assessed correlations
between the two measures and the risk of malaria.
Materials and Methods
Study site and recruitment of study participants
Participants for a randomized comparison of three combination
antimalarial regimens were recruited from the Mulago III parish
of Kampala, Uganda, as previously described [33]. In Kampala,
malaria is mesoendemic, with a parasite prevalence of ,20% in
children ages two to nine years measured in 2004. Interim results
of the clinical study have been published (isrctn.org identifier:
ISRCTN37517549) [34]. Following a census, random households
were selected to participate in the study, and 601 children, aged
one to ten years, were recruited. The children were followed for
two years beginning on April 1, 2005. Rainy seasons occur in
March-May and September-November [33]. Subjects were not
enrolled if they were severely malnourished, had a known adverse
reaction to any study medication, had a known serious chronic
disease, or were diagnosed with a life-threatening condition after a
baseline laboratory screen.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The clinical trial and this study
were approved by the Uganda National Council of Science and
Technology and Institutional Review Boards of Makerere
University and the University of California, San Francisco. All
patients’ parents or guardians provided written informed consent
for the collection of samples and subsequent analysis.
Assessment of malarial incidence
All participants were asked to come to a study clinic for all their
healthcare needs; the clinic was open seven days a week. Episodes
of malaria were diagnosed by passive surveillance, and, in
addition, subjects were assessed every 30 days. Subjects presenting
to the clinic with fever (tympanic temperature $38.0uC) or history
of fever in the previous 24 h had a thick blood smear assessed for
parasites. If the smear was positive, the participant was treated for
malaria, regardless of parasite density. Molecular genotyping was
performed to distinguish new infections (incident events) from
recrudescences (which were not considered incident events),
following a step-wise algorithm including assessment of polymor-
phisms in the P. falciparum genes msp1, msp2, and four
microsatellites [34,35]. Treatment failures within three days of
diagnosis were considered recrudescences and not counted as
incident events. Further details regarding this cohort have been
published [8].
Laboratory techniques
Fresh whole blood samples were collected at enrollment and
sent to a certified lab in Kampala for G6PD activity assessment. A
single assessment was performed by estimating the rate of NADPH
production from NADP using a commercially available quantita-
tive spectrophotometric test (Randox Laboratories, Ardmore, UK,
catalog number PD410). Strict adherence to manufacturer’s
protocol was followed including appropriate use of control
samples. The manufacturer reports G6PD values as mU/109
erythrocytes, and recommends a cutoff of 110 mU/109 erythro-
cytes to differentiate normal from deficient G6PD activity.
For genotyping of G6PD, blood was collected on filter paper,
and DNA was extracted using the QIAamp DNA Mini Kit
(Qiagen, Valencia, CA). A specimen was unavailable for one
individual, leaving a sample population of 600 individuals.
Genotypes for the G6PD A- variant (G202A, rs1050828) were
determined by PCR followed by restriction endonuclease
digestion. PCR was performed using 26 PCR Master Mix
(Fermentas, Glen Burnie, MD; 0.05 U/ml Taq Polymerase
(recombinant), 4 mM MgCl2, and 0.4 mM of each dNTP),
0.2 mM of each primer (as described elsewhere [27]), 5% DMSO,
and approximately 10 ng of DNA. Thermocycling was performed
on a DNA Engine Dyan (MJ Research Inc., Waltham, MA). An
initial denaturation at 94uC for 10 minutes was followed by 40
cycles of 94uC for 30 seconds, 68uC for 30 seconds, and 72uC for
30 seconds with a final extension of 72uC for 7 minutes. PCR
products (10 ml) were incubated with 5 U of NlaIII at 37uC for
three hours, and genotypes were determined by inspection of
digestion products after 2.5% agarose gel electrophoresis.
In 110 randomly selected samples, genotypes for the G6PD A
variant (G376A, rs1050829) were determined by PCR as above
with primers as previously described [26]. Amplifications condi-
tions were as above except for an annealing temperature of 55uC,
followed by incubation with 5 U of FokI at 37uC for two hours
before electrophoresis and visual determination of genotypes.
Sixteen individuals who were found to be enzymatically
deficient but were genotyped as wild-type for the 202 variant
were sequenced to assess other alleles that define the G6PD A-
variant (G680T and T968C). The amplification reactions were
performed as described above, using primers described elsewhere
[25]. Thermocycling conditions were as above, except for an
annealing temperature of 65uC. Sequencing of PCR products was
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performed by the University of California San Francisco
Genomics Core Facility.
Statistical analysis
Statistical analysis was performed using Stata version 10 (Stata,
College Station, TX). Predictor variables included age, sex, sickle
cell trait, G6PD enzyme deficiency, G6PD genotype, bed net
usage, materials used in household construction, household water
source, and index of household wealth, household crowding,
antimalarial treatment arm, and distance from potential mosquito
breeding sites. Time-dependent covariates (age, bed net use, and
calendar time) were evaluated at the precision of 1 day. Our
outcome measure was malaria incidence, as measured by incident
episodes of malaria per person-year at risk. Subjects who were in
the cohort as of April 1, 2005, but were terminated from the study
prior to completion of follow-up contributed person-time equiv-
alent to the duration of time they spent in the study.
Univariate and multivariate analyses using generalized estimat-
ing equations with control for repeated measures in the same
subject were used to estimate associations between predictor
variables of interest and malaria. P,0.05 was considered
statistically significant. Variables that were significant in univariate
analysis were included in the multivariate model.
Results
Baseline G6PD levels
A total of 600 individuals, consisting of 289 females and 311
males, were tested for G6PD enzyme activity (Figure 1). The shapes
of the distributions differed, with the enzyme activity in males
following a normal distribution and that in females more closely
approximating a bimodal distribution. Based on the manufacturer’s
cutoff value of ,110 mU/109 erythrocytes, 20 females (6.9%) and
42 males (13.5%) had deficient G6PD enzyme activity.
Genotyping for the A- Allele
Thirty-six males (11.6%) were hemizygous, 61 females (21.1%)
were heterozygous and five females (1.7%) were homozygous for
the G202A mutation. The allele frequency of G202A was 0.12 for
both males and females. All genotypes were in Hardy-Weinberg
equilibrium. To confirm that the G202A mutation occurred only
in the background of the G376A mutation, we genotyped 110
randomly selected samples for the G6PD A variant. Of these 110
samples, 23 carried the G202 mutation, all of which also carried
the G376A mutation. No individuals carried the G376A mutation
in isolation.
Correlation between G6PD genotype and phenotype
Enzyme activity was stratified by gender and genotype
(Figure 2). The median value of enzyme activity was 216 mU/
109 erythrocytes (Interquartile Range (IQR) = 80) for wild-type
males and 61 mU/109 erythrocytes (IQR=38.5) for hemizygous
males with the G202A allele. For females, the median value of
enzyme activity was 225 mU/109 erythrocytes (IQR=101) for
wild-type females, 135 mU/109 erythrocytes (IQR=77) for
heterozygous females, and 63 mU/109erythrocytes (IQR=148)
for homozygous G6PD A- females. Figure 1 also reveals that while
the majority of genotypically-deficient females fell into the first
peak of the bimodal enzyme distribution, a significant proportion
of genotypically-deficient individuals had higher enzyme levels.
Only 6 of 269 (2%) males with normal G6PD enzyme activity
carried the G6PD A- allele (Table 1). However, of the 269 females
with normal enzyme activity, 48 (18%) were heterozygous and two
(1%) were homozygous for the A- allele. Of the 42 males with
deficient enzyme activity, 12 (29%) were wild-type at the A- allele.
In the 20 females determined to have deficient enzyme activity, 4
(20%) were wild-type at the A- allele. Neither of the other
mutations classified as G6PD A- variants (G680T and T968C)
were found in the 16 individuals genotyped as wild-type for the
G202A allele but found to be enzyme deficient.
We assessed the sensitivity and specificity of the phenotypic test
as compared to genetic analysis. For this analysis heterozygous
females were classified as deficient. Using a cutoff of 110 mU/
10‘9 erythrocytes to define G6PD deficiency in males, the test was
83.3% sensitive and 95.6% specific. In males, the test had a
positive predictive value of 71.4% and a negative predictive value
of 97.7%. In females, the test was 24.2% sensitive and 98.2%
specific, with a positive predictive value of 80.0% and a negative
predictive value of 81.4%.
G6PD deficiency and the risk of malaria
We previously showed in this cohort that G6PD deficiency, as
assessed solely by enzymatic assay, was associated with a
significantly lower risk of uncomplicated malaria in females
(relative risk (RR)= 0.48, 95% CI 0.31–0.75, p-value = 0.001)
but not males (RR=0.83, 95% CI 0.55–1.26, p-value = 0.39) [8].
With genetic results now available, we assessed the difference in
risk of malaria between G6PD deficient individuals, as defined by
enzymatic assay or genotype (Table 2). Notably, no association
was seen between the incidence of uncomplicated malaria and the
G6PD A- genotype in heterozygous and homozygous females
(RR=0.99, 95% CI 0.70–1.39, p-value = 0.95) or hemizygous
males (RR=0.79, 95% CI 0.52–1.23, p-value = 0.30; Table 2). As
Figure 1. Distribution of G6PD enzyme activity (mU/109 erythrocytes) in all individuals, males, and females. For the male and female
distributions, G6PD A- genotype data are also displayed, with wild-type individuals represented by a dark gray bar and hemizygous, heterozygous,
and homozygous individuals by a light gray bar.
doi:10.1371/journal.pone.0007246.g001
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expected, the RRs for other predictor variables examined did not
change between this study and our prior analysis.
As seen in both Table 1 and Figure 1, females defined as
genotypically deficient (heterozygotes or homozygotes) were not
uniformly identified as deficient by enzyme activity, a phenom-
enon explained largely by X chromosome inactivation. Thus, we
repeated the association analysis, comparing the relative risk of
uncomplicated malaria in females defined as both genotypically
and enzymatically deficient to those females who were both
genotypically wild-type and enzymatically normal. Indeed, females
defined as deficient by both methods were protected from malaria
compared with females defined as non-deficient by both methods
(RR=0.57, 95% CI 0.37–0.88). As before, males defined as
deficient by genotype and enzyme activity did not appear
significantly protected from uncomplicated malaria (RR 0.84,
95% CI 0.52–1.32).
Lastly, we assessed the impact of altering the cutoff value for the
enzymatic test on our genetic association analysis (Table 3). At
cutoff values between 90 (RR=0.47, 95% CI 0.30–0.74, p-
value = 0.001) and 120 (RR=0.46, 95% CI 0.28–0.76, p-
value = 0.002) mU/109 erythrocytes, enzymatic G6PD deficiency
was significantly associated with a decreased risk of uncomplicated
malaria in females (Table 3). Considering cut-off values
.120 mU/109 erythrocytes, no association was seen between
G6PD deficiency and uncomplicated malaria in females. Sample
sizes for females with levels ,90 were insufficient for meaningful
statistical analysis. Notably, no significant association between
G6PD deficiency and uncomplicated malaria was seen in males,
even at a cut-off of ,70 mU/109 erythrocytes.
Discussion
Genetic association studies have provided inconsistent results on
the relationship between G6PD deficiency and the risk of malaria,
particularly uncomplicated malaria. Differences between studies
include varied study designs, sample sizes, inclusion of other
known genetic modifiers (ie. sickle cell), and differences in the
malaria phenotype being assessed. A potential major source of
discrepancy between studies was the method of screening for
G6PD deficiency. We compared the results of the association
between G6PD deficiency and malaria using both enzymatic and
genetic assessments. We found that G6PD deficiency had no
significant association with the incidence of uncomplicated malaria
in males regardless of which assay was used. However, in females,
when G6PD deficiency was defined by enzyme activity, deficiency
was associated with a 52% reduced risk of uncomplicated malaria.
This level of protection was comparable to that seen in individuals
who use insecticide-treated bed nets (RR=0.51) and somewhat
greater than that conferred by sickle cell trait (RR=0.68) [8].
Interestingly, the significant association between malaria incidence
and G6PD phenotype in females was lost when G6PD status was
defined by G6PD genotype (RR=0.99 for heterozygous/homo-
zygous females compared to wild-type females). However, in our
cohort, out of 61 female heterozygotes, only 13 were defined as
enzymatically deficient. Thus, we compared the risk of malaria in
heterozygous/homozygous females who were also enzymatically
deficient to the risk of malaria in those who were defined as
normal by both assays. Notably, the ‘‘dually’’ deficient group was
significantly protected from uncomplicated malaria. In other
words, G6PD deficiency protected against uncomplicated malaria,
but only in females when deficiency was measured enzymatically.
It is possible that the varied results in prior association studies that
have relied on genotypic testing may be explained due to the
mosaic distribution of enzyme activity in heterozygous females.
As described earlier, the mosaic distribution of G6PD deficiency
is due to variable X chromosome inactivation [36]. This
characteristic explains, in large part, the lack of correlation
between genotypic and enzymatic assays for the detection of
G6PD deficiency. The overall prevalence of G6PD deficiency in
males was similar between the genotypic (14% deficient) and
enzymatic (12% deficient) assays. However, the assays did not
correlate exactly, as almost 30% of males who were enzymatically
deficient were wild-type for the G6PD A- allele. More strikingly, as
noted above, we found a significant discrepancy between G6PD
genotype and phenotype for females. Only 20 females (7%) were
deficient by enzymatic assay, while 66 (23%) were genotyped as
heterozygous or homozygous for the G6PD A- allele. Such
findings may be of concern in instances where screening is
performed to determine one’s risk of drug-induced hemolysis [37].
Indeed, a recent trial of the antimalarial chlorproguanil-dapsone/
artesunate found an unacceptably high rate of dapsone-induced
hemolytic anemia in both homozygous and heterozygous females
[38]. Given the low sensitivity of the enzymatic test for identifying
heterozygous females, a significant number of females may be
placed at risk of hemolysis if enzymatic screening is utilized in such
settings [38].
Table 1. Correlation of Phenotype with Genotype by Gender.
Gender Phenotype N Genotype N Enzyme Activity
Mean Range
Male Normal 269 Wild-type 263 (98%) 218 110–436
Hemizygous 6 (2%) 211 132–316
Deficient 42 Wild-type 12 (29%) 93 67–108
Hemizygous 30 (71%) 59 32–93
Female Normal 269 Wild-type 219 (81%) 222 116–385
Heterozygous 48 (18%) 202 152–252
Homozygous 2 (1%) 165 110–272
Deficient 20 Wild-type 4 (20%) 100 88–107
Heterozygous 13 (65%) 96 68–108
Homozygous 3 (15%) 57 47–63
doi:10.1371/journal.pone.0007246.t001
Figure 2. Dot plot showing the distribution of G6PD enzyme
activity stratified by genotype.
doi:10.1371/journal.pone.0007246.g002
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Table 2. Association of predictor variables with the incidence of malaria.
Category Group
New episodes
of malaria
Person
time (yrs)
Incidence
of malaria Multivariate analysisa Multivariate analysisb
RR (95% CI) p-value RR (95% CI) p-value
Age Less than 6 years of age 305 338.1 0.90 1.0 - 1.0 -
6 years or older 390 562.5 0.69 0.85 (0.70–1.04) 0.11 0.84 (0.69–1.02) 0.08
Sickle cell AA 608 743.9 0.82 1.0 - 1.0 -
AS 87 156.7 0.56 0.68 (0.52–0.90) 0.007 0.68 (0.52–0.90) 0.007
G6PD Activity Normal female 290 391.8 0.74 1.0 -
Deficient female 11 36.5 0.30 0.48 (0.31–0.75) 0.001
Normal male 345 401.5 0.86 1.0 -
Deficient male 49 70.8 0.69 0.83 (0.55–1.26) 0.39
G6PD Genotype Wild-type female 228 318.5 0.72 1.0 -
Homo/heterozygous female 75 110.2 0.68 0.99 (0.70–1.39) 0.95
Wild-type male 352 411.7 0.85 1.0 -
Hemizygous male 40 56.2 0.71 0.79 (0.52–1.23) 0.30
Bed net use None 322 336.4 0.96 1.0 - 1.0 -
Untreated 173 205.9 0.84 0.85 (0.68–1.07) 0.17 0.86 (0.69–1.08) 0.20
Insecticide treated 200 358.3 0.56 0.51 (0.32–0.83) 0.006 0.52 (0.32–0.83) 0.007
Wealth index 1st or 2nd quartile 420 421.4 1.00 1.0 - 1.0 -
3rd quartile 155 234.4 0.66 0.83 (0.62–1.10) 0.20 0.83 (0.63–1.10) 0.20
4th quartile 120 244.8 0.49 0.77 (0.56–1.04) 0.09 0.78 (0.57–1.06) 0.11
Crowding 3 or less persons per room 268 471.5 0.57 1.0 - 1.0 -
More than 3 persons per room 427 429.1 1.00 1.24 (0.98–1.57) 0.007 1.24 (0.98–1.57) 0.007
Distance from swamp More than 200 meters from swamp 56 164.1 0.34 1.0 - 1.0 -
101–200 meters from swamp 119 233.0 0.51 1.39 (0.91–2.10) 0.12 1.40 (0.92–2.13) 0.11
1–100 meters from swamp 357 409.7 0.87 2.16 (1.51–3.10) ,0.001 2.21 (1.54–3.18) ,0.001
Living in swamp 163 93.8 1.74 3.94 (2.61–5.97) ,0.001 4.07 (2.67–6.18) ,0.001
NOTE RR, relative risk.
aPreviously published results from Table 1 [8], showing results of regression analysis using G6PD deficiency defined by enzyme assay.
bRepeat regression analysis using G6PD deficiency defined by genotype. Note that RR for other covariates remain constant.
doi:10.1371/journal.pone.0007246.t002
Table 3. Effect of G6PD activity cut-off criteria on the association analysis of G6PD status and malaria incidence.
G6PD Activity Cut-off Point
(mU/109 erythrocytes) Enzymatically Deficient Female Enzymatically Normal Male/Female Enzymatically Deficient Male
N RR (95% CI) P-value RR (95% CI) P-value N RR (95% CI) P-value
,70 4* 0.70 (0.42–1.20) 0.2 1 - 23 1.08 (0.70–1.68) 0.73
,80 4* 0.71 (0.42–1.20) 0.2 1 - 26 0.97 (0.61–1.53) 0.9
,90 8* 0.47 (0.30–0.74) 0.001 1 - 31 0.89 (0.57–1.37) 0.59
,100 10 0.58 (0.33–1.02) 0.061 1 - 39 0.82 (0.53–1.27) 0.37
,110 20 0.48 (0.31–0.75) 0.001 1 - 42 0.83 (0.55–1.26) 0.38
,120 33 0.46 (0.28–0.76) 0.002 1 - 51 0.87 (0.60–1.30) 0.53
,130 44 0.81 (0.52–1.26) 0.36 1 - 62 0.94 (0.65–1.33) 0.7
,140 61 0.93 (0.65–1.32) 0.69 1 - 73 0.88 (0.62–1.25) 0.49
,150 74 1.02 (0.74–1.42) 0.9 1 - 78 0.81 (0.57–1.16) 0.25
NOTE: N, represents the total number of individuals who have a G6PD activity level below the specified cut-off point; RR, relative risk.
NOTE: Table depicts how the relative risk of malaria varies depending on the cut-off point for determining G6PD deficiency by enzymatic assay.
*Sample sizes are too small for meaningful analysis of enzymatically deficient females in these categories.
doi:10.1371/journal.pone.0007246.t003
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To further explore the relationship between G6PD enzyme
activity and the risk of malaria, we determined whether the degree
of deficiency affected an individual’s risk of malaria. With a cutoff
of 90–120 mU/109 erythrocytes, G6PD deficiency was consis-
tently protective in females, with risk reductions between 42–54%.
However, at higher cutoff values (,130 mU/109 erythrocytes),
protection from malaria was not seen. These results suggest that
lower levels of enzyme activity are protective against malaria in
females. Sample sizes were too small to meaningfully assess the
association of levels of G6PD enzyme activity levels ,90 mU/109
erythrocytes in females. Notably, however, there was no evidence
of a protective effect against uncomplicated malaria in the 23
males with the lowest G6PD activity levels (,70 mU/109
erythrocytes). Prior studies have seen protection from malaria
primarily in heterozygous females [14]. These findings have led to
the hypothesis that in the face of a mosaic population of deficient
erythrocytes, the malaria parasite is unable to efficiently adapt and
produce its own G6PD enzyme [39].
Of 62 people with enzymatically determined G6PD deficiency,
we were unable to identify a deficiency-causing variant in ,25%
(16/62) after assessing the three common G6PD A- variants found
in African populations. Most notably, nearly 1 in 3 males who
were enzymatically deficient, were wild-type at the G202A,
G680T and T968C loci. It is likely that other mutations exist
and that they may mediate altered enzyme activity in these
individuals [32]. Full sequencing of the G6PD gene in our East
African individuals is planned. Conversely, of the 538 individuals
determined to have normal G6PD activity, a small minority
(8/538) were homozygous or hemizygous for the G6PD A-
variant. Normal enzyme level in these individuals might have been
due to recent hemolysis, as reticulocytes have five times higher
activity than older red blood cells [23]. We were not able to
measure reticulocytes, but we did not detect any association
between G6PD level and history of treatment for malaria within
the two weeks preceding G6PD activity testing.
This study underscores the impact that the method of
identifying G6PD deficient individuals has upon studies of
G6PD deficiency and malaria. We found that G6PD-deficient
females, but not males, were significantly protected against
uncomplicated malaria, but this protection was only seen when
G6PD deficiency was described using enzyme activity. The lack of
association seen in heterozygous females was likely due to the
mosaic population of erythrocytes, as protection was again seen
when the analysis was restricted to females who were both
heterozygous and enzymatically deficient. These observations may
help to explain discrepancies in some published association studies
involving G6PD deficiency and uncomplicated malaria. Ultimate-
ly, it may be that both methods have a role in the detection and
characterization of G6PD deficiency. In the setting of association
studies, whilst enzymatic assays seem to more closely approximate
biologic function and correlate with protection, the addition of
genetic testing may uncover novel disease causing variants and
thereby aid in our understanding of this widespread enzymopathy.
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